



## SAFETY DATA SHEET

Page 1 of 5 - Date of Issue: 15 November 2016

**IMPORTANT NOTICE** This Safety Data Sheet (SDS) is prepared by Seqirus Pty. Ltd. in accordance with Safe Work Australia National Code of Practice for the Preparation of Safety Data Sheets (February 2016). The information contained herein must not be altered or deleted. Additional information may be appended to the SDS, but it must be marked clearly to indicate that it is not part of the original.

---

### 1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER

**Product Name** Q-VAX<sup>®</sup> Q Fever Vaccine; Q-VAX<sup>®</sup> Skin Test

**Other Names** Not applicable

**Manufacturer's Product Code** 09800501 vaccine (pre-filled syringe); 09960501 skin test (vial)

**Use** For the immunisation of susceptible adults at identifiable risk of infection with Q fever. Testing is required **before** vaccination, see product information leaflet.

As with other injectable vaccines, appropriate medical treatment and supervision should always be available in case of anaphylactic reactions. Adrenaline should always be readily available whenever the injection is given.

**Supplier Name** Seqirus Pty Ltd (ABN 26 160 735 035)

**Address** 63 Poplar Road, Parkville, Victoria 3052, Australia

**Telephone** +61 3 9389 2000

**Emergency Telephone** +61 3 9389 1984 (24hr)

---

### 2. HAZARDS IDENTIFICATION

**Not classified as a hazardous chemical according to Australian WHS Regulations**

**GHS Classification(s)** None Allocated

**Signal Word** No Signal Word

**Pictogram(s)** No Pictogram(s)

**Hazard Statement(s)** None Allocated

**Prevention statement(s)** None Allocated

**Response** None Allocated

---

**Storage** None Allocated

**Disposal** None Allocated

---

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

<i>Chemical Name:</i>	<i>CAS Number:</i>	<i>Proportion:</i>
Formalin inactivated, <i>Coxiella burnetii</i>	-	≥25µg vaccine (per 0.5mL); ≥5µg skin test (per 1mL)
Thiomersal	54-64-8	0.01%
Other Non-Hazardous Ingredients	-	up to 100%

---

### 4. FIRST AID MEASURES

- Accidental Injection** Flush injection site with water. Seek medical attention.
- Eye** Flush eye thoroughly with water for at least 15 minutes. If irritation occurs, seek immediate medical attention.
- Swallowed** DO NOT induce vomiting. Wash out mouth with water and give plenty of water to drink. If hypersensitivity occurs, seek medical attention immediately
- Skin** Remove contaminated clothing. Wash skin thoroughly with water. If irritation occurs, seek medical attention.
- Aggravated Medical Conditions** An allergic reaction may occur in individuals with hypersensitivity to egg proteins. Serious hypersensitivity can occur in individuals who have previously had the illness Q fever or been given the vaccine Q-VAX<sup>®</sup>.
- Advice to Doctor** Treat symptomatically.
- 

### 5. FIRE FIGHTING MEASURES

- Fire/Explosion Hazard** Non-combustible. Not considered a significant fire risk. Where possible, contain and collect fire-fighting water for later disposal.
- Fire Extinguishing Media** No restrictions.
- Hazchem Code** None allocated
- 

### 6. ACCIDENTAL RELEASE MEASURES

- Minor Spills**
- Wear protective gloves and safety glasses.
  - Clean up spill immediately using absorbent paper towels.
-

- 
- |                     |  |
|---------------------|--|
| <b>Major Spills</b> | - Place spilled material in clean, dry, sealed container for disposal. |
|                     | - Wash area with copious amounts of water.                             |
|                     | - Wear protective gloves and safety glasses.                           |
|                     | - Contain and absorb spills using earth, sand or inert absorbent.      |
- |  |   |
|--|---|
|  | - Collect residues and seal in labelled drums for disposal. |
|  | - Wash area with copious amounts of water.                  |
- 

## 7. HANDLING AND STORAGE

- Transport and store at 2 to 8 degrees C (do not freeze).
  - Protect from light.
  - Store as per Schedule 4 pharmaceutical.
- 

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

**Exposure Standards** No exposure limits set by SWA or ACGIH

**Engineering Controls** None under normal operating conditions.

**Personal Protection** For good infection control, gloves should be worn when administering an injection.

The local concentration of material, quantity and conditions of use determine the type of personal protective equipment required. For further information, consult your Occupational Health and Safety Adviser.

---

## 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance** Clear liquid

**Odour** Slight odour.

**pH** 6.9 to 7.4

**Boiling Point/Melting Point** Not determined

**Vapour Pressure** Not determined

**Vapour Density** Not determined

**Specific Gravity** Not determined

**Flashpoint** Not determined

**Flammability Limits** Not determined

**Solubility in Water** Aqueous solution

---

## 10. STABILITY AND REACTIVITY

**Reactivity** Not known to be incompatible with any other material.

**Stability** Stable under anticipated storage and handling conditions (refer section 7).

**Decomposition Products** Not determined

---

## 11. TOXICOLOGICAL INFORMATION

**Accidental Injection** Tenderness/redness at injection site. An allergic reaction may occur in individuals with hypersensitivity to egg proteins. Serious hypersensitivity can occur in individuals who have previously had the illness Q fever or received the vaccine Q-VAX<sup>®</sup>. Local abscess formation may occur at the site of injection.

**Eye** May cause mild irritation.

**Swallowed** May cause irritation of the gastro-intestinal tract. In hypersensitive individuals, may precipitate an acute allergic reaction. Severe allergic reactions will usually occur within the first few hours of ingestion.

Symptoms of an allergic reaction may include shortness of breath; swelling of the face, lips, tongue, or other parts of the body; skin rash, itching or hives.

**Skin** May cause mild irritation.

**Inhaled** Not an expected route of exposure.

**Chronic Health Effects** Chronic fatigue syndrome has been very rarely reported following clinical use of Q-VAX<sup>®</sup>.

---

## 12. ECOLOGICAL INFORMATION

- No data available.
  - For good environmental practice avoid discharge to waterways.
- 

## 13. DISPOSAL CONSIDERATIONS

- In accordance with state land and waste management authority.
  - For good environmental practice avoid discharge into waterways.
- 

## 14. TRANSPORT INFORMATION

**Not Classified as a dangerous good by the criteria of the ADG Code**

---

---

<b>UN Number</b>	None allocated
<b>DG Class</b>	None allocated
<b>Subsidiary Risk</b>	None allocated
<b>Packing Group</b>	None allocated
<b>Hazchem Code</b>	None allocated

---

## 15. REGULATORY INFORMATION

**Poisons Schedule Number** Schedule 4 (S4) – Prescription only medicine

---

## 16. OTHER INFORMATION

**Last Revised** 15 November 2016

**Reason for Revision**

- Update to GHS requirements
- Update Business contact details
- Update Composition and Physical properties information
- Updated NOHSC to SWA

### Abbreviations

SWA	- Safe Work Australia
GHS	- Globally Harmonised System
WHS	- Work, Health and Safety
ADG Code	- Australian Dangerous Goods Code
UN Number	- United Nations Number
DG Class	- Dangerous Goods Class
CAS Number	- Chemical Abstract Service Number

### Contact Point

Company Contact:	+61 3 9389 1984 (24hr)
Australian Poisons Information Centre, 24 hour service:	13 11 26
Australian Police, Fire Brigade or Ambulance:	000
New Zealand Poisons Information Centre, 24 hour service:	0800 764 766
New Zealand Police, Fire Brigade or Ambulance:	111

---

Whilst the information contained in this document is based on data which, to the best of our knowledge, was accurate and reliable at the time of preparation, no responsibility can be accepted by us for errors and omissions. Users are advised to make their own determination as to the suitability of this information in relation to their particular purposes and specific circumstances. Since the information contained in this document may be applied under conditions beyond our control, we can accept no responsibility for any loss or damage by any person acting or refraining from action as a result of this information.

---